Capital Research Global Investors Trims Stake in Stryker Corporation $SYK

Capital Research Global Investors reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,966,567 shares of the medical technology company’s stock after selling 307,737 shares during the period. Capital Research Global Investors’ holdings in Stryker were worth $2,097,071,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in shares of Stryker in the second quarter worth approximately $205,000. Marshall Wace LLP boosted its position in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new position in shares of Stryker in the second quarter worth approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the second quarter worth approximately $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock worth $100,659,489 over the last 90 days. 4.60% of the stock is owned by insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $305.71 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a fifty day moving average price of $318.43 and a 200 day moving average price of $345.86. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The firm has a market cap of $117.20 billion, a price-to-earnings ratio of 35.38, a P/E/G ratio of 1.93 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the company posted $2.84 EPS. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, UBS Group dropped their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.